Ishares Msci Spain ETF vs Revvity Inc — how do they compare? Ishares Msci Spain ETF trades at $57.9 (market cap $2.30B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 7.4× Ishares Msci Spain ETF's market cap, and Revvity Inc pays a 0.18% dividend while Ishares Msci Spain ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Spain ETF for 41 Days and Revvity Inc for 12 Days on average.
| EWP | RVTY | |
|---|---|---|
Market Cap | $2.30B | $16.98B |
Volume | 845,747 | 1,456,900 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.23 | $157.36 |
52-Week Low | $48.33 | $82.26 |
Typical Hold Time | 41 Days | 12 Days |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
EWP, the iShares MSCI Spain ETF, trades at $57.90 with minimal daily movement (+0.14%). Technical indicators show a bearish trend with strong selling pressure across moving averages and oscillators. The ETF offers exposure to Spanish equities at a discounted valuation with a 2.7% yield, though concentrated in financials and utilities. Recent ECB rate hikes and energy price volatility create macroeconomic headwinds for European markets.
The outlook remains cautious given bearish technical signals and eurozone economic pressures. Attractive valuation and dividend yield provide support, but concentration risk and monetary policy tightening pose challenges. Further upside depends on Spanish economic resilience and stabilization of energy inflation.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →